Participants in the trial take several capsules (which might be bexarotene or a placebo) a day for 6 months and remyelination is assessed by one MRI scan at the beginning of this six-month period and one at the end.
The trial centres are at Cambridge and Edinburgh.
Participants need to live reasonably close to these centres as frequent visiting (at times weekly) is required.
Participants should have relapsing-remitting multiple sclerosis, need to be able to walk, and should be taking a first-line disease-modifying drug (especially Tecfidera, etc.).
If you wish to be considered for the trial, please ask your GP or consultant to refer you to:
Prof Alasdair Coles
Department of Clinical Neurosciences,
Clifford Albutt Building, Level 4,
Cambridge Biomedical Campus,
Cambridge CB2 0AH
Dr Peter Connick
The Anne Rowling Regenerative Neurology Clinic
University of Edinburgh
49 Little France Crescent
Edinburgh EH16 4SB